A Glucose Metabolism-Modulatory Nanobiohybrid Vaccine Platform Promotes Anti-Tumor Immunity by Orchestrating Autophagy-Dependent Cross-Presentation and H

Weidong Wang, Yimin Gong, Jianing Li, Tianze Wu, Mingli Deng, Yannan Yang

Abstract read

In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Weidong WangShanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, China.

Yimin GongShanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, China.

Jianing LiShanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, China.

Tianze WuState Key Laboratory of Genetics and Development of Complex Phenotypes, Obstetrics and Gynecology Hospital, Children's Hospital, Fudan University, Shanghai, China.

Mingli DengShanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, China.

Yannan YangSouth Australian Immunogenomics Cancer Institute, The University of Adelaide, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0001-6696-3879

Funding

Australia National Health and Medical Research Council 2010100National Natural Science Foundation of China 22275037

6 · The paper itself

Abstract

The clinical translation of cancer vaccines remains limited by the inability to effectively coordinate innate and adaptive immunity. Leveraging the metabolism pattern of the immune system, herein, we report a glucose metabolism-modulatory nanobiohybrid vaccine with superior antitumor immunity via orchestrating cross-presentation-enhanced adaptive immunity and proinflammatory signaling-mediated innate immunity. This nanobiohybrid vaccine is constructed by a nanoscale hydrogen-bonded organic framework (HOF) co-encapsulating glucose oxidase (GOx), and a model antigen, ovalbumin (OVA) (denoted OVA/GOx@HOF). OVA/GOx@HOF enables a GOx-mediated enzyme reaction that consumes glucose and produces H

Indexed as

autophagycancer immunotherapyhydrogen sulfidenanobiohybridsNLRP3 inflammasome

Identifiers

PMID42478736

DOI10.1002/advs.76654

PMCPMC13386600

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.